Mike Clayman's guest appearances

Mike Clayman

Empowered Patient Podcast

ForbesBooks Radio

Becker’s Healthcare Podcast

Biotech 2050 Podcast

Seth Lederman

Karen Zaderej

Brian Culley

Jonathan Javitt

Paula Ragan

James Mackay

Jim Woody

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Robert Gould

Chris Young

Jim Martin

OwlTail

Mike Clayman, M.D., Chief Executive Officer and Co-Founder, Flexion Therapeutics brings us up to speed on the work at Flexion developing and commercializing new treatments for musculoskeletal disorders (MSDs) including osteoarthritis (OA) knee pain. Mike also talks about how the company has been adapting to the COVID-19 pandemic to get their drug Zilretta out to patients in need. @FlexionInc #musculoskeletaldisorder #OAK #kneepain #osteoarthritisofknee #MSD #COVID19 FlexionTherapeutics.com Download the transcript here

Mike Clayman, M.D., Chief Executive Officer and Co-Founder, Flexion Therapeutics brings us up to speed on the work at Flexion developing and commercializing new treatments for musculoskeletal disorders (MSDs) including osteoarthritis (OA) knee pain. Mike also talks about how the company has been adapting to the COVID-19 pandemic to get their drug Zilretta out to patients in need. @FlexionInc #musculoskeletaldisorder #OAK #kneepain #osteoarthritisofknee #MSD #COVID19 <a href="http://flexiontherapeutics.com" rel="noopener nofollow" target="_blank">FlexionTherapeutics.com</a> <a href="http://empoweredpatientradio.com/new-treatments-for-musculoskeletal-disorders-with-dr-mike-clayman-flexion-therapeutics-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

New Treatments for Musculoskeletal Disorders with Dr. Mike Clayman Flexion Therapeutics

Dr. Clayman is a co-founder of Flexion Therapeutics and has served as our President, Chief Executive Officer and as one of our directors since our inception in 2007. Dr. Clayman also serves as the Chairman of the board of directors of both Anokion SA and Ribometrix. Previously, Dr. Clayman had a lengthy career at Eli Lilly and Company, where he was most recently Vice President, Lilly Research Laboratories, and General Manager of Chorus, Lilly’s early-phase development accelerator. During his career at Lilly, Dr. Clayman also led its Global Regulatory Affairs division, the Cardiovascular Discovery Research and Clinical Investigation, Research and Development at Advanced Cardiovascular Systems, a medical device subsidiary of Lilly, the Internal Medicine Division, the Lilly Clinic, Lilly’s dedicated Phase 1 unit, and served as Chair of Lilly’s Bioethics Committee. Prior to his tenure at Lilly, Dr. Clayman was an Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the immunopathogenesis of renal disease. Dr. Clayman is the recipient of the Physician Scientist Award from the National Institutes of Health.  Dr. Clayman earned a B.A., cum laude, from Yale University and an M.D. from the University of California, San Diego School of Medicine. Following an internship and residency in Internal Medicine at the University of California, San Francisco Moffitt Hospitals, Dr. Clayman completed clinical and research fellowships in Nephrology at the University of Pennsylvania.

19. Mike Clayman, MD, CEO and Co-Founder, Flexion Therapeutics